Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (2018)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1016/j.jacc.2018.03.002
- Subjects: ANTI-INFLAMATÓRIOS; DOENÇAS CARDIOVASCULARES; DIABETES MELLITUS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of the american college of cardiology
- ISSN: 0735-1097
- Volume/Número/Paginação/Ano: v. 71, n. 21, p. 2392-2401, 2018
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
- Licença: publisher-specific-oa
-
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 09 jan. 2026. -
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002 -
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2026 jan. 09 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002 -
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2026 jan. 09 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002 - Oclusão de comunicação interventricular pós-infarto com prótese percutânea CERA
- Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
- Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial
- The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54
- Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes
- P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes
- Extent of coronary and myocardial disease and benefit from surgical revascularization in LV dysfunction
Informações sobre o DOI: 10.1016/j.jacc.2018.03.002 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
